Tethys to push diabetes risk test with $25m
This article was originally published in Clinica
Executive Summary
Tethys Bioscience is to ramp up commercialisation of its diabetes risk test, PreDx, after raising $25m in a series B financing round. Lead investor in the round was aeris CAPITAL; other participants in the fundraising include Tethys' existing shareholders and new investor Wasatch Advisors.
You may also be interested in...
Could Alcon's CyPass Trouble Be Boon For Glaukos – Or Bust For MIGS?
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roche Dx' EMEA Head To Take Charge After Diggelmann Departs
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.
Nose For A Good Tech? Philips Adds Nasal Alar Pulse Oximetry To Monitoring Portfolio
Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.